Overview of recent advances in metastatic triple negative breast cancer

Table 3 Early studies of Immunotherapy and chemotherapy in metastatic triple negative breast cancer

Trial	n	Drug	ORR 1st line	ORR ≥ 2 line	mOS 1st line	mOS 2nd line	Ref.
NCT01633970 Phase Ib	33	Atezolizumab + nab-paclitaxel	53.8%	30	24.2	12.4	Adams et al[55], 2019
KEYNOTE-150 Phase 1b/II	82	Pembrolizumab + Eribulin	25%	26.5	17.7	NE	Tolaney et al[57], 2018
Pilot and phase II. 1-2L1	29	Pembrolizumab + capecitabine or paclitaxel	43% pembro + cap. 23% pembro + paclitaxel		13.8 pembro + cap 7.9 pembro + pac		Page et al[90], 2019

¹One to two lines of prior treatment. Pembro: Pembrolizumab; Cap: Capecitabine; Pac: Paclitaxel; ORR: Overall response rate; OS: Overall survival.